Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 2;11(2):174.
doi: 10.3390/cancers11020174.

Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review

Denise Fabian  1 , Maria Del Pilar Guillermo Prieto Eibl  2 , Iyad Alnahhas  3 , Nikhil Sebastian  4 , Pierre Giglio  5 , Vinay Puduvalli  6 , Javier Gonzalez  7 , Joshua D Palmer  8
Affiliations
Review

Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review

Denise Fabian et al. Cancers (Basel). .

Abstract

Glioblastoma (GBM) is the most common primary brain tumor. Despite aggressive treatment, GBM almost always recurs. The current standard-of-care for treatment of newly diagnosed GBM has remained relatively unchanged since 2005: maximal safe resection followed by concomitant chemoradiation (CRT) with temozolomide (TMZ), and subsequent adjuvant TMZ. In 2011, the first-generation tumor treating fields (TTF) device, known at the time as the NovoTTF-100A System (renamed Optune), was approved by the Food and Drug Administration (FDA) for treatment of recurrent GBM. The TTF device was subsequently approved as an adjuvant therapy for newly-diagnosed GBM in 2015. The following is a review of the TTF device, including evidence supporting its use and limitations.

Keywords: GBM; TTF; glioblastoma; tumor treating fields.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J.B., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466. doi: 10.1016/S1470-2045(09)70025-7. - DOI - PubMed
    1. Thakkar J.P., Dolecek T.A., Horbinski C., Ostrom Q.T., Lightner D.D., Barnholtz-Sloan J.S., Villano J.L. Epidemiologic and Molecular Prognostic Review of Glioblastoma. Cancer Epidemiol. Biomark. Prev. 2014;23:1985–1996. doi: 10.1158/1055-9965.EPI-14-0275. - DOI - PMC - PubMed
    1. Gilbert M.R., Wang M., Aldape K.D., Stupp R., Hegi M.E., Jaeckle K.A., Armstrong T.S., Wefel J.S., Won M., Blumenthal D.T., et al. Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. J. Clin. Oncol. 2013;31:4085–4091. doi: 10.1200/JCO.2013.49.6968. - DOI - PMC - PubMed
    1. Gilbert M.R., Dignam J.J., Armstrong T.S., Wefel J.S., Blumenthal D.T., Vogelbaum M.A., Colman H., Chakravarti A., Pugh S., Won M., et al. A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. N. Engl. J. Med. 2014;370:699–708. doi: 10.1056/NEJMoa1308573. - DOI - PMC - PubMed
    1. Chinnaiyan P., Won M., Wen P.Y., Rojiani A.M., Werner-Wasik M., Shih H.A., Ashby L.S., Michael Yu H.H., Stieber V.W., Malone S.C., et al. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913. Neuro-Oncology. 2018;20:666–673. doi: 10.1093/neuonc/nox209. - DOI - PMC - PubMed